Tech Company Financing Transactions
Autoimmunity BioSolutions Funding Round
Autoimmunity BioSolutions closed a $2 million Seed funding round on 11/28/2024. Backers included Eos Bioinnovation, Alexandria Venture Investments and Independent Capital Partners.
Transaction Overview
Company Name
Announced On
11/28/2024
Transaction Type
Venture Equity
Amount
$2,000,000
Round
Seed
Investors
Proceeds Purpose
The company intends to use the funds to enhance the development of its lead program, which consisted of monoclonal antibodies specifically targeting sIL7R while sparing membrane-bound IL7R.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
1455 Louisiana Avenue 4207
League City, TX 77573
USA
League City, TX 77573
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Next-Generation, Immuno-Corrective Therapy for Treatment of Autoimmune Diseases by Targeting a Novel, Fundamental Autoimmune Pathway Driven by Upregulation of the Soluble Interleukin 7 Receptor (sIL7R). Autoimmunity BioSolutions (ABS) is developing a next-generation, immuno-corrective therapy to restore normal immune function in a genetically-defined subpopulation of autoimmune disease patients in which the autoimmune pathology is driven by a SNP that enhances the expression of sIL7R.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Eugene Williams
Chief Scientific Officer
Gaddiel Galarza-Muñoz
Browse more venture capital transactions:
Prev: 11/28/2024: Kilter venture capital transaction
Next: 11/29/2024: Zenno Astronautics venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to record all VC transactions involving tech companies. VC investment data records on this site are derived from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs